Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of synthetic polysulphated oligosaccharides as cleaning agents for a wound

A technology of polysulfated oligosaccharides and detergents, which is applied in the direction of active carbohydrate ingredients, medical preparations containing active ingredients, drug combinations, etc., and can solve the problems of slow action and insufficient removal of a large amount of fibrin tissue

Inactive Publication Date: 2012-10-31
HCP HEALTHCARE ASIA
View PDF13 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] However, they act slowly and are not sufficient to remove large amounts of fibrinous tissue

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Example 1: Demonstration of the effect of sucrose octasulfate potassium salt degradation in degrading fibrin matrices prepared in vitro

[0106] 1. Preparation of Fibrin Matrix in Vitro

[0107] Fibrin matrices were prepared according to Brown's experimental notes described in "Fibroblast migration in fibrin gel matrices" (Am J. Pathol, 1993, 142: 273-283).

[0108] The components and procedures used are as follows:

[0109] Dissolve the following substances at 37°C:

[0110] - 5 ml of an aqueous solution containing 50 mmoles of Hepes (Sigma-Aldrich Catalog);

[0111] - 15 mg of human plasma fibrinogen (Sigma-Aldrich Catalog);

[0112] -5 mmol CaCl 2 .

[0113] To the solution thus prepared was added 50 µl of thrombin, 100 NIH of human plasma (Sigma-Aldrich Catalog).

[0114] The reaction mixture was mixed, added to 15 ml tubes (or 60 mm diameter Petri dishes), and incubated at 37°C.

[0115] During the first 24 h of incubation at 37°C, the appearance of a rough,...

Embodiment 2

[0142] Example 2: Demonstration of the effect of sucrose octasulfate potassium salt on fibrin tissue taken from the body

[0143] The same solution of potassium sucrose octasulfate was tested on fibrinous tissue removed from the body.

[0144] For this test, a 5mm 2 Fibrin tissue samples were placed in 15ml tubes incubated at 37°C.

[0145] After 24 h, 1 ml of sucrose octasulfate potassium salt solution was deposited on the samples.

[0146] Prepare negative control with PBS again, use Prepare a positive control.

[0147] PDFs were determined 48h after the introduction of the active substance or the control.

[0148] This experiment was repeated on 5 fibrin tissue samples obtained from the same patient.

[0149] Thus, it was found that sucrose octasulfate potassium salt completely degrades the fibrin matrix in this test, demonstrating its effectiveness.

[0150] This result was confirmed by the determination of the PDFs as follows:

[0151] Higher than 20μg / ml;

[0...

Embodiment 3

[0155] Example 3: Demonstration of the effectiveness of sucrose octasulfate potassium salt incorporated into absorbent dressings in degrading fibrin matrices prepared in vitro

[0156] 1. Preparation of Absorbent Dressings Containing Potassium Sucrose Octasulfate

[0157] Using thermal bonding technology, with the help of TOYOBOCOLTD company sold F superabsorbent fibers and bicomponent thermally bonded polyester / polyethylene fibers (ratio of 70% superabsorbent fibers / 30% thermally bonded fibers), prepared to be used as absorbent dressings in case of autolytic cleaning 180g / m used 2 non-woven fabric.

[0158] Separately, a hydrocolloid viscous mass comprising sucrose octasulfate potassium salt was prepared by mixing in a MEL G-40 mixer.

[0159] The composition of this viscous mass is expressed in weight percent relative to the total weight of the viscous mass as follows:

[0160] - by the Shell company to Mineral oil sold under the name 917: 32.8%;

[0161] -CMC by AQU...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to the use of at least one compound selected among the synthetic polysulphated oligosaccharides having 1 to 4 ose units and to the salts and complexes thereof as cleaning agents for a wound. The invention can be used in particular for preparing bandages intended for cleaning wounds.

Description

technical field [0001] The present invention relates to the use of at least one compound selected from the group consisting of synthetic polysulfated oligosaccharides having 1 to 4 monosaccharide units and their salts and complexes as cleaning agents. [0002] More precisely, the present invention relates to the use of at least one of said compounds as a degrader of the fibrin matrix, which is a constituent of fibrinous tissue. In particular, the present invention relates to the preparation of compositions for use in auxiliary cleaning situations. Background technique [0003] Wound healing is a natural biological phenomenon in which human and animal tissues are able to repair local damage through their intrinsic repair and regeneration processes. [0004] The natural healing of wounds proceeds in three consecutive phases, each of which is characterized by specific cellular activities that allow the repair process to proceed in a precise chronological order: a cleansing pha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/70A61F13/00A61P17/02A61K31/7016A61K31/702
CPCA61L2300/404A61L15/28A61L15/18A61K31/702A61L2300/41A61F13/00A61L15/44A61L2300/232A61K31/7016A61L2300/45A61L15/60A61K45/06A61K31/155A61K31/167A61K31/7024A61P17/02A61K2300/00A61K31/70
Inventor 洛朗·阿佩尔克里斯特勒·劳伦索多米尼克·尼科
Owner HCP HEALTHCARE ASIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com